COINS Seminar #16

Liposome-based cancer nanomedicines - DOXIL and beyond

Alberto A. Gabizon, MD, PhD

Professor and Chairman,

Shaare Zedek Oncology InstituteHebrew University-School of Medicine

Jerusalem, ISRAEL

日時：2016 年 5 月 12 日（木）15：30～16：30（受付開始　15:00）
会場：ナノ医療イノベーションセンター（iCONM）4 階　4101 号室
交流会：同日 16:30～18:00 会費 500 円
定員：40 名
申込：メール事前登録制、「氏名」「ご所属」「お役職」「交流会参加有無」「メールアドレス」を COINS 支援事務局宛にメールでお申込みください。
Email: jimukyoku-coins@kawasaki-net.ne.jp

—Abstract—

Cancer chemotherapeutic agents lack selectivity and have problematic toxicities. Nanoparticles provide effective control of the release rate and tissue distribution of these agents, leading to major pharmacokinetic and pharmacodynamic changes. PEG coating of liposomes results in significant prolongation of residence time in the blood stream. A hallmark of these long-circulating liposomes is their enhanced accumulation in tumors by a mechanism known as enhanced permeability and retention effect. An example of nanomedicine with demonstrated clinical added value in cancer therapy is PEG-liposomal doxorubicin (DOXIL®), which has demonstrated clinically a favorable safety profile with an impressive reduction in cardiac toxicity and proven efficacy against various malignancies and can be considered as the first anti-cancer nanomedicine approved for clinical use. Other liposomal formulations recently approved for clinical use hold promise in cancer chemotherapy. Another approach in liposomal drug delivery combines a stable and long-circulating liposome with chemical modification of a drug to form a lipophilic prodrug with strong association to the liposomal bilayer. This is the case of a prodrug of mitomycin-C (MMC) activated by thiolytic cleavage. PEG-liposomal MMC prodrug (Promitil®) is more effective and less toxic than conventional chemotherapy in the treatment of various animals and human tumor models. A recently completed phase 1 study of Promitil shows a 3-fold reduction in toxicity as compared to free MMC. Co-encapsulation of synergistic agents in the same nanoparticle is another valuable approach in liposome delivery, particularly if toxicities do not overlap. Co-encapsulation of a drug and an imaging agent can provide real-time imaging of drug biodistribution using the nanocarrier as a theranostic platform. Furthermore liposome-based nanomedicines offer a unique tool for other manipulations including the grafting of tumor-specific ligands for active targeting to tumor cells and enhanced intracellular drug delivery. Results of these innovative approaches using the pegylated liposomal platform will be presented.

***主催: JST　COI プログラム**
スマートライフケア社会への変革を先導するものづくりオープンイノベーション拠点（COINS）
研究統括　片岡一則　（川崎市産業振興財団 ナノ医療イノベーションセンター　センター長）

＊問い合わせ先：川崎市産業振興財団 COINS 支援事務局　TEL: 044-589-5785
E-mail: jimukyoku-coins@kawasaki-net.ne.jp　Web: http://coins.kawasaki-net.ne.jp/

＜会場へのアクセス＞
住所：
〒210-0821　神奈川県川崎市川崎区殿町 3-25-14
交通：
　電車の方は　京急川崎駅から 京急大師線 「小島新田」下車 乗車時間約 10 分　 徒歩約 1５分
　バスの方は
　「JR 川崎駅 東口ターミナル」
■20 番のりば
・川 02「殿町」行き乗車（臨港バス）乗車時間約 30 分「殿町」下車　徒歩約 3 分
・急行　快速「浮島橋」行き乗車（臨港バス）乗車時間約 20 分「キングスカイフロント入口」
　下車　徒歩約 5 分
■16 番のりば
・川 03「浮島バスターミナル」行き乗車（臨港バス　又は　川崎市営バス）乗車時間約 30 分
「キングスカイフロント入口」下車　徒歩約 5 分

川崎生命科学・環境研究センター（LiSE）の隣です。